Evidence map›Paper›PMID 42438298›Full record

ArticleBritish journal of haematology2026

DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia.

Qiao Liu, Xuechun Wang, Jiqiang Fan, Yi Zheng, Luya Ye, Wenhan Chang, Xianglei Chen, Yuanhua Cai, Xiaolin Lai, Yang Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qiao LiuFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Xuechun WangFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Jiqiang FanSchool of Life Sciences, Xiamen University, Xiamen, Fujian Province, China.
Yi ZhengFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Luya YeFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Wenhan ChangCenter for RNA Biology and Therapeutics, Beckman Research Institute of the City of Hope, Duarte, California, USA.
Xianglei ChenDepartment of Hematology, Weifang Yidu Central Hospital, Qingzhou, Shandong, China.ORCID https://orcid.org/0000-0003-1607-9967
Yuanhua CaiFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Xiaolin LaiFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Yang LiFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Lili PanFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Xiaofan LiFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.ORCID https://orcid.org/0000-0002-6460-7210
RenJang LinCenter for RNA Biology and Therapeutics, Beckman Research Institute of the City of Hope, Duarte, California, USA.ORCID https://orcid.org/0000-0002-2738-2438
Shaoyuan WangFujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.

Funding

Fujian Provincial Clinical Research Center for Hematological Malignancies 2020Y2006Fujian Provincial Department of Science and Technology 2020J011300Fujian Provincial Finance Department 2023CZ006National Key Clinical Specialty Discipline Construction Program of China 2021-76National Natural Science Foundation of China 81770163National Natural Science Foundation of China 82070157National Natural Science Foundation of China 82300166Natural Science Foundation of Fujian Province 2024J01595
6 · The paper itself

Abstract

The AML1-ETO (AE) fusion gene, resulting from t(8;21)(q22;q22), represents a prevalent subtype of acute myeloid leukaemia (AML). Retention of exon 9a between exon 8 and 9 of the ETO (RUNX1 Partner Transcriptional Co-Repressor 1, also name RUNX1T1) gene generates the oncogenic AML1-ETO9a (AE9a) splice variant. Here, we uncover the potential involvement of RNA (ribonucleic acid) helicase DHX15 (DEAH-box helicase 15) in AE9a splicing and AML progression. Clinically, higher expressed DHX15 is associated with increased AE9a/AE abundance and poor outcomes in AE-positive (AE

Indexed as

Core Binding Factor Alpha 2 SubunitDEAD-box RNA HelicasesLeukemia, Myeloid, AcuteOncogene Proteins, FusionRNA-Binding ProteinsRNA HelicasesRNA SplicingRUNX1 Translocation Partner 1 ProteinAnimalsCell Line, TumorHumansMaleMiceAML1-ETO fusion protein, humanCore Binding Factor Alpha 2 SubunitDEAD-box RNA HelicasesDHX15 protein, humanOncogene Proteins, FusionRNA-Binding ProteinsRNA HelicasesRUNX1 Translocation Partner 1 ProteinAMLAML1‐ETOAML1‐ETO9aDHX15RNA splicing

Identifiers

PMID42438298
PMCPMC13570222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.